These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 34896116)
1. Positioning Ozanimod in Ulcerative Colitis: Restoring Leukocyte Traffic Under Control. D'Amico F; Allocca M; Fiorino G Gastroenterology; 2022 May; 162(6):1767-1769. PubMed ID: 34896116 [No Abstract] [Full Text] [Related]
2. Ozanimod for the Treatment of Ulcerative Colitis. Khanna R; Chande N; Marshall JK Gastroenterology; 2022 Jun; 162(7):2104-2106. PubMed ID: 35122762 [No Abstract] [Full Text] [Related]
3. Update on ozanimod for ulcerative colitis. Antonelli EK; Del Sordo R; Morelli O; Villanacci V; Bassotti G Drugs Today (Barc); 2022 Jul; 58(7):351-367. PubMed ID: 35851870 [TBL] [Abstract][Full Text] [Related]
4. Ozanimod for Ulcerative Colitis. Macaluso FS; Orlando A N Engl J Med; 2022 Jan; 386(2):194. PubMed ID: 35020993 [No Abstract] [Full Text] [Related]
5. Ozanimod for Ulcerative Colitis. Senussi NH; Rakov N N Engl J Med; 2022 Jan; 386(2):194. PubMed ID: 35020994 [No Abstract] [Full Text] [Related]
6. Ozanimod for Ulcerative Colitis. Reply. Sandborn WJ; Danese S N Engl J Med; 2022 Jan; 386(2):194-195. PubMed ID: 35020995 [No Abstract] [Full Text] [Related]
7. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008 [TBL] [Abstract][Full Text] [Related]
8. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A; N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850 [TBL] [Abstract][Full Text] [Related]
9. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Aoun R; Hanauer S Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):411-423. PubMed ID: 35400292 [TBL] [Abstract][Full Text] [Related]
10. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Rowan C; Ungaro R; Mehandru S; Colombel JF Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955 [TBL] [Abstract][Full Text] [Related]
11. Ozanimod (Zeposia) for ulcerative colitis. Med Lett Drugs Ther; 2021 Sep; 63(1633):147-151. PubMed ID: 34550962 [No Abstract] [Full Text] [Related]
12. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors. Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447 [TBL] [Abstract][Full Text] [Related]
13. Modulation of sphingosine-1-phosphate in ulcerative colitis. Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531 [No Abstract] [Full Text] [Related]
14. Ozanimod: First Approval. Lamb YN Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738 [TBL] [Abstract][Full Text] [Related]
15. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072 [TBL] [Abstract][Full Text] [Related]
17. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. Taylor Meadows KR; Steinberg MW; Clemons B; Stokes ME; Opiteck GJ; Peach R; Scott FL PLoS One; 2018; 13(4):e0193236. PubMed ID: 29608575 [TBL] [Abstract][Full Text] [Related]
18. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. Fronza M; Lorefice L; Frau J; Cocco E Drug Des Devel Ther; 2021; 15():1993-2004. PubMed ID: 34007159 [TBL] [Abstract][Full Text] [Related]
19. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Jairath V; Peyrin-Biroulet L; Zou G; Mosli M; Vande Casteele N; Pai RK; Valasek MA; Marchal-Bressenot A; Stitt LW; Shackelton LM; Khanna R; D'Haens GR; Sandborn WJ; Olson A; Feagan BG; Pai RK Gut; 2019 Jul; 68(7):1162-1168. PubMed ID: 30076171 [TBL] [Abstract][Full Text] [Related]
20. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. Boland BS; Vermeire S Gastroenterol Clin North Am; 2017 Sep; 46(3):627-644. PubMed ID: 28838419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]